Free Float -
Shares Float -
Shares Outstanding 17,7 M
LYSOGENE S.A.(PROM.)-,30
Share · FR0013233475 · A2DLMU (XPAR)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of LYSOGENE S.A.(PROM.)-,30
No Price
Share Float & Liquidity
Company Profile for LYSOGENE S.A.(PROM.)-,30 Share
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was incorporated in 2009 and is based in Neuilly-sur-Seine, France.
Company Data
Name LYSOGENE S.A.(PROM.)-,30
Company Lysogene S.A.
Website
https://www.lysogene.com
Primary Exchange 
Paris
Paris
WKN A2DLMU
ISIN FR0013233475
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Karen Pignet-Aiach MBA
Country France
Currency EUR
Employees 0,0 T
Address 18-20 rue Jacques Dulud, 92200 Neuilly-sur-Seine
IPO Date 2017-02-08
Ticker Symbols
| Name | Symbol |
|---|---|
| Paris | LYS.PA |
More Shares
Investors who hold LYSOGENE S.A.(PROM.)-,30 also have the following shares in their portfolio:
